Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2011

Open Access 01-12-2011 | Research

Nuclear beta-catenin overexpression in metastatic sentinel lymph node is associated with synchronous liver metastasis in colorectal cancer

Authors: Hongxia Cheng, Hui Liang, Yejun Qin, Ying Liu

Published in: Diagnostic Pathology | Issue 1/2011

Login to get access

Abstract

Background

Beta-catenin, a component of the Wingless/Wnt signaling pathway, can activate target genes linking with the adenomatous polyposis coli (APC) gene in colorectal cancer. The purpose of this study is to investigate whether nuclear beta-catenin overexpression in metastatic sentinel lymph node(s) [SLN(s)] is associated with synchronous liver metastasis.

Methods

Clinicopathological data from 355 patients (93 cases with liver metastasis and 262 cases without liver metastasis) were reviewed. Beta-catenin expression in metastatic SLN(s) and liver metastatic lesions was examined by immunohistochemistry. The association of nuclear beta-catenin expression in metastatic SLN(s) and liver metastatic lesions was evaluated, and the relationship between nuclear beta-catenin expression and clinicopathological characteristics was analyzed. Finally, univariate and logistic multivariate regression analyses were adopted to discriminate the risk factors of liver metastasis.

Results

Nuclear beta-catenin overexpression in metastatic SLN(s) was observed in 70 patients with liver metastasis and 31 patients without liver metastasis (75.3% vs. 11.8%; P < 0.001). Nuclear beta-catenin expression was noted in all the metastatic lesions. Spearman rank correlation analysis demonstrated that nuclear beta-catenin expression in metastatic SLN(s) had a positive correlation with that in metastatic lesions (r = 0.425, P < 0.001). Univariate and multivariate analyses indicated that nuclear beta-catenin overexpression in metastatic SLN(s) correlated with liver metastasis.

Conclusions

Nuclear beta-catenin overexpression in metastatic SLN(s) is strongly associated with liver metastasis and may contribute to predict liver metastasis.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E: Cancer statistics 2004. CA Cancer J Clin. 2004, 54: 8-29. 10.3322/canjclin.54.1.8.CrossRefPubMed
2.
Laffer UT, Metzger U: Intraportal chemotherapy for colorectal hepatic metastases. World J Surg. 1995, 19: 246-51. 10.1007/BF00308634.CrossRefPubMed
3.
Barozzi C, Ravaioli M, D'Errico A, Grazi GL, Poggioli G, Cavrini G, et al.: Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel. Cancer. 2002, 94: 647-57. 10.1002/cncr.10278.CrossRefPubMed
4.
Chen Z, Li M, Yuan Y, Wang Q, Yan L, Gu J: Cancer/testis antigens and clinical risk factors for liver metastasis of colorectal cancer: a predictive panel. Dis Colon Rectum. 2010, 53: 31-8. 10.1007/DCR.0b013e3181bdca3a.CrossRefPubMed
5.
Iwaya K, Oikawa K, Semba S, Tsuchiya B, Mukai Y, Otsubo T, et al.: Correlation between liver metastasis of the colocalization of actin-related protein 2 and 3 complex and WAVE2 in colorectal carcinoma. Cancer Sci. 2007, 98: 992-9. 10.1111/j.1349-7006.2007.00488.x.CrossRefPubMed
6.
Kaio E, Tanaka S, Kitadai Y, Sumii M, Yoshihara M, Haruma K, et al.: Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma. Oncology. 2003, 64: 61-73. 10.1159/000066511.CrossRefPubMed
7.
Sasaki A, Iwashita Y, Shibata K, Matsumoto T, Ohta M, Inomata M, et al.: Risk factors for early extrahepatic metastasis in patients with liver metastasis from colorectal carcinoma. Hepatogastroenterology. 2005, 52: 1840-4.PubMed
8.
Talbot IC, Ritchie S, Leighton MH, Hughes AO, Bussey HJ, Morson BC: The clinical significance of invasion of veins by rectal cancer. Br J Surg. 1980, 67: 439-42. 10.1002/bjs.1800670619.CrossRefPubMed
9.
Yamazoe Y, Maetani S, Onodera H, Nishikawa T, Tobe T: Histopathological prediction of liver metastasis after curative resection of colorectal cancer. Surg Oncol. 1992, 1: 237-44. 10.1016/0960-7404(92)90070-2.CrossRefPubMed
10.
Adachi Y, Inomata M, Kakisako K, Sato K, Shiraishi N, Kitano S: Histopathologic characteristics of colorectal cancer with liver metastasis. Dis Colon Rectum. 1999, 42: 1053-6. 10.1007/BF02236702.CrossRefPubMed
11.
De Jong KP, Stellema R, Karrenbeld A, Koudstaal J, Gouw AS, Sluiter WJ, et al.: Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology. 1998, 28: 971-9.CrossRefPubMed
12.
Nanashima A, Yamaguchi H, Sawai T, Yasutake T, Tsuji T, Jibiki M, et al.: Expression of adhesion molecules in hepatic metastases of colorectal carcinoma: relationship to primary tumours and prognosis after hepatic resection. J Gastroenterol Hepatol. 1999, 14: 1004-9. 10.1046/j.1440-1746.1999.01991.x.CrossRefPubMed
13.
Fujita S, Taniguchi H, Yao T, Shimoda T, Ueno H, Hirai T, et al.: Multi-institutional study of risk factors of liver metastasis from colorectal cancer: correlation with CD10 expression. Int J Colorectal Dis. 2010, 25: 681-6. 10.1007/s00384-010-0913-x.CrossRefPubMed
14.
Ohji Y, Yao T, Eguchi T, Yamada T, Hirahashi M, Iida M, et al.: Evaluation of risk of liver metastasis in colorectal adenocarcinoma based on the combination of risk factors including CD10 expression: multivariate analysis of clinicopathological and immunohistochemical factors. Oncol Rep. 2007, 17: 525-30.PubMed
15.
Brabletz S, Schmalhofer O, Brabletz T: Gastrointestinal stem cells in development and cancer. J Pathol. 2009, 217: 307-17. 10.1002/path.2475.CrossRefPubMed
16.
Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T: Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer. 2005, 5: 744-9. 10.1038/nrc1694.CrossRefPubMed
17.
Fodde R, Brabletz T: Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol. 2007, 19: 150-8. 10.1016/j.ceb.2007.02.007.CrossRefPubMed
18.
Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, et al.: Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA. 2001, 98: 10356-61. 10.1073/pnas.171610498.PubMedCentralCrossRefPubMed
19.
Harris TJ, Peifer M: Decisions, decisions: beta-catenin chooses between adhesion and transcription. Trends Cell Biol. 2005, 15: 234-7. 10.1016/j.tcb.2005.03.002.CrossRefPubMed
20.
van EJH, Barker N, Clevers H: You Wnt some, you lose some: oncogenes in the Wnt signaling pathway. Curr Opin Genet Dev. 2003, 13: 28-33. 10.1016/S0959-437X(02)00012-6.CrossRef
21.
Bandapalli OR, Dihlmann S, Helwa R, Macher-Goeppinger S, Weitz J, Schirmacher P, et al.: Transcriptional activation of the beta-catenin gene at the invasion front of colorectal liver metastases. J Pathol. 2009, 218: 370-9. 10.1002/path.2539.CrossRefPubMed
22.
Bagaria SP, Faries MB, Morton DL: Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer Institute. J Surg Oncol. 2010, 101: 669-76. 10.1002/jso.21581.PubMedCentralCrossRefPubMed
23.
van AAC, Voit CA, Verhoef C, Eggermont AM: New developments in sentinel node staging in melanoma: controversies and alternatives. Curr Opin Oncol. 2010, 22: 169-77. 10.1097/CCO.0b013e328337aa78.CrossRef
24.
Kelley MC, Hansen N, McMasters KM: Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Am J Surg. 2004, 188: 49-61. 10.1016/j.amjsurg.2003.10.028.CrossRefPubMed
25.
Newman EA, Newman LA: Lymphatic mapping techniques and sentinel lymph node biopsy in breast cancer. Surg Clin North Am. 2007, 87: 353-64. 10.1016/j.suc.2007.01.013. viiiCrossRefPubMed
26.
Bembenek A, Gretschel S, Schlag PM: Sentinel lymph node biopsy for gastrointestinal cancers. J Surg Oncol. 2007, 96: 342-52. 10.1002/jso.20863.CrossRefPubMed
27.
Dionigi G, Castano P, Rovera F, Boni L, Annoni M, Villa F, et al.: The application of sentinel lymph node mapping in colon cancer. Surg Oncol. 2007, 16 (Suppl 1): S129-32.CrossRefPubMed
28.
Bilchik AJ, Giuliano A, Essner R, Bostick P, Kelemen P, Foshag LJ, et al.: Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms. Cancer J Sci Am. 1998, 4: 351-8.PubMed
29.
Dragan R, Nebojsa M, Dejan S, Ivan P, Dragos S, Damir J, et al.: Clinical application of sentinel lymph node biopsy for staging, treatment and prognosis of colon and gastric cancer. Hepatogastroenterology. 2009, 56: 1606-11.PubMed
30.
He ZY, Wen H, Shi CB, Wang J: Up-regulation of hnRNP A1, Ezrin, tubulin beta-2C and Annexin A1 in sentinel lymph nodes of colorectal cancer. World J Gastroenterol. 2010, 16: 4670-6. 10.3748/wjg.v16.i37.4670.PubMedCentralCrossRefPubMed
31.
Greene FL, Page DL: AJCC Cancer Staging Manual. 2002, New York, NY: Springer-Verlag, 127-38. 6CrossRef
32.
Smith FM, Coffey JC, Khasri NM, Walsh MF, Parfrey N, Gaffney E, et al.: Sentinel nodes are identifiable in formalin-fixed specimens after surgeon-performed ex vivo sentinel lymph node mapping in colorectal cancer. Ann Surg Oncol. 2005, 12: 504-9. 10.1245/ASO.2005.08.019.CrossRefPubMed
33.
Romeo S, Bovee JV, Grogan SP, Taminiau AH, Eilers PH, Cleton-Jansen AM, et al.: Chondromyxoid fibroma resembles in vitro chondrogenesis, but differs in expression of signalling molecules. J Pathol. 2005, 206: 135-42. 10.1002/path.1782.CrossRefPubMed
34.
Brembeck FH, Rosario M, Birchmeier W: Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev. 2006, 16: 51-9. 10.1016/j.gde.2005.12.007.CrossRefPubMed
35.
Brabletz T, Jung A, Kirchner T: Beta-catenin and the morphogenesis of colorectal cancer. Virchows Arch. 2002, 441: 1-11. 10.1007/s00428-002-0642-9.CrossRefPubMed
36.
Canavese G, Bernardi A, Candelaresi G, Lovadina P, Amerio S, Rossetti V, et al.: Expression of the E-cadherin-catenins complex in sentinel node is related to tumor morphology but not to spread to nonsentinel nodes. Pathol Res Pract. 2007, 203: 517-23. 10.1016/j.prp.2007.03.003.CrossRefPubMed
37.
Zhang B, Ougolkov A, Yamashita K, Takahashi Y, Mai M, Minamoto T: beta-Catenin and ras oncogenes detect most human colorectal cancer. Clin Cancer Res. 2003, 9: 3073-9.PubMed
38.
Baldus SE, Monig SP, Huxel S, Landsberg S, Hanisch FG, Engelmann K, et al.: MUC1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin Cancer Res. 2004, 10: 2790-6. 10.1158/1078-0432.CCR-03-0163.CrossRefPubMed
39.
da FLM, da LMM, Lacerda-Filho A, Cabral MM, da SRG: Colorectal carcinoma in different age groups: A histopathological analysis. Int J Colorectal Dis. 2011,
40.
O'Connell JB, Maggard MA, Liu JH, Etzioni DA, Ko CY: Are survival rates different for young and older patients with rectal cancer. Dis Colon Rectum. 2004, 47: 2064-9. 10.1007/s10350-004-0738-1.CrossRefPubMed
41.
Liang H, Wang XN, Wang BG, Pan Y, Liu N, Wang DC, et al.: Prognostic factors of young patients with colon cancer after surgery. World J Gastroenterol. 2006, 12: 1458-62.PubMedCentralPubMed
42.
Savas N, Dagli U, Akbulut S, Yuksel O, Sahin OB: Colorectal cancer localization in young patients: should we expand the screening program. Dig Dis Sci. 2007, 52: 798-802. 10.1007/s10620-006-9432-6.CrossRefPubMed
Metadata
Title
Nuclear beta-catenin overexpression in metastatic sentinel lymph node is associated with synchronous liver metastasis in colorectal cancer
Authors
Hongxia Cheng
Hui Liang
Yejun Qin
Ying Liu
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2011
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-6-109

Other articles of this Issue 1/2011

Diagnostic Pathology 1/2011 Go to the issue

Research

Tissue print of prostate biopsy: a novel tool in the diagnostic procedure of prostate cancer

Research

Aberrant antigenic expression in extranodal NK/T-cell lymphoma: a multi-parameter study from Thailand

Case Report

Mesothelioma of tunica vaginalis of "uncertain malignant potential" - an evolving concept: case report and review of the literature

Research

Proteomic patterns analysis with multivariate calculations as a promising tool for prompt differentiation of early stage lung tissue with cancer and unchanged tissue material

Research

ABCG2 is associated with HER-2 Expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma

Research

Diagnostic utility of p63/P501S double sequential immunohistochemical staining in differentiating urothelial carcinoma from prostate carcinoma